A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands

Oral Oncology

Volumn 43, Issue 1, 2007, Pages 33-36

  Pfeffer, M Raphael ^a,b   Talmi, Yoav ^a,b   Catane, Raphael ^a,b   Symon, Zvi ^a,b   Yosepovitch, Ady ^a   Levitt, Mark ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adenoid cystic; Carcinoma; Imatinib; Salivary glands; Therapy

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

ADENOID CYSTIC CARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SCREENING; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MALE; METASTASIS; PERIORBITAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALIVARY GLAND CARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, ADENOID CYSTIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SALIVARY GLAND NEOPLASMS;

EID: 33846557908     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2005.12.026     Document Type: Article

References (22)

1. Holst V.A., Marshall C.E., Moskaluk C.A., and Frierson H.F. C-kit protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Modern Pathol 12 (1999) 956-960
2. Went P.T., Dirnhofer S., Bundi M., et al. Prevalence of KIT expression in human tumours. J Clin Oncol 22 (2004) 4214-4222
3. Jeng Y.-M., Lin C.-Y., and Hsu H.-C. Expression of c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 154 (2000) 107-111
4. Joensuu H., and Dimitrijevic S. Tyrosine kinase inhibitor Imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 33 (2001) 451-455
5. Van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of Imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358 (2001) 1421-1423
6. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
7. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose Imatinib: randomized trial. Lancet 364 (2004) 1127-1134
8. Parsons J.T., Mendenhall W.M., Stringer S.P., Cassisi N.J., and Million R.R. Management of minor salivary gland carcinomas. Int J Radiat Oncol Biol Phys 35 (1996) 443-454
9. Khan A.J., DiGiovanna M.P., Ross D.A., et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer 96 (2001) 149-158
10. Tannock I.F., and Sutherland D.J. Chemotherapy for adenocystic carcinoma. Cancer 46 (1980) 452-454
11. Hill M.E., Constenla D.O., A'Hern R.P., et al. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 33 (1997) 275-278
12. Airoldi M., Pedani F., Succo G., et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91 (2001) 541-547
13. Airoldi M., Fornari G., Pedani F., et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res 20 (2000) 3781-3783
14. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 347 (2002) 472-480
15. Hotte S.J., Winquist E.W., Lamont E., et al. Imatinib mesylate in patients with adenoid cystic carcinoma of the salivary glands expressing c-kit. A Princess Margaret Hospital phase II consortium study. J Clin Oncol 23 (2005) 585-590
16. Ochel H.J., Gademann G., Rocken C., and Wordehoff H. Effects of Imatinib mesylate on adenoid cystic carcinomas. Anticancer Res 25 (2005) 3659-3664
17. Alcedo J.C., Fabrega J.M., Arosemena J.R., and Urrutia A. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck 26 (2004) 829-831
18. Faivre S., Raymond E., Casiraghi O., Temam S., and Berthaud P. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 23 (2005) 6271-6273
19. Heinrich M.C. Is KIT an important therapeutic target in small cell lung cancer?. Clin Cancer Res 9 (2003) 5880-5887
20. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumours. J Clin Oncol 22 (2004) 3813-3825
21. Johnson B.E., Fischer T., Fischer B., et al. Phase II study of Imatinib in patients with small cell lung cancer. Clin Cancer Res 9 (2003) 5880-5887
22. Frierson Jr. H.F., El-Naggar A.K., Welsh J.B., et al. Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol 161 (2002) 1315-1323